HC Wainwright Estimates Immunic FY2024 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Immunic in a research report issued on Monday, November 25th. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.95) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Immunic’s FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.23) EPS.

Several other research analysts also recently commented on the company. B. Riley started coverage on Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price for the company. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners reissued an “outperform” rating and set a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Immunic currently has an average rating of “Buy” and a consensus target price of $11.80.

Immunic Price Performance

Immunic stock opened at $1.14 on Wednesday. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The stock has a fifty day moving average of $1.38 and a 200-day moving average of $1.34.

Insider Buying and Selling

In related news, Director Richard Alan Rudick bought 87,300 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $1.15 per share, with a total value of $100,395.00. Following the acquisition, the director now owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC bought a new stake in Immunic in the first quarter valued at approximately $9,266,000. Vanguard Group Inc. boosted its stake in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the last quarter. Ikarian Capital LLC increased its position in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.